Молекулярные механизмы инициирования и модуляции ауто-иммунного процесса микроорганизмами

Инфекционные агенты являются наиболее известными экологическими факторами, провоцирующими и модулирующими аутоиммунные заболевания. Молекулярные механизмы, лежащие в основе этого явления, включают молекулярную мимикрию, распространение эпитопов и обеспечение доступности криптических эпитопов аутоантигенов, активацию в присутствии свидетеля, эффект адъюванта, поликлональную активацию В-лимфоцитов и Т-лимфоцитов бактериальными суперантигенами. Непатогенные микроорганизмы и инфекционные агенты могут также защищать людей от аутоиммунных заболеваний посредством активации регуляторных Т-лимфоцитов и смещения равновесия между Т-лимфоцитами-хелперами классов 1 и 2 в пользу последних.

аутоиммунные заболевания, молекулярная мимикрия, распространение эпитопов, доступность криптических эпитопов, эффект адъюванта, суперантигены

1. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity – friends or foes? Trends in Immunology 2009 Aug; 30(8): 409–14.

2. Ercolini A.M., Miller S.D. The role of infections in autoimmune dis-ease. Clin Exp Immunol 2009 Jan; 155(1): 1–15.

3. Ceccarelli F., Agmon-Levin N., Perricone C. Genetic factors of autoimmune diseases. J Immunol Res 2017 Nov 5; 2017: 2789242.

4. Mariani S.M. Genes and autoimmune diseases - a complex inheritance. Med Gen Med 2004 Dec 8; 6(4): 18.

5. Ramos P.S, Shedlock A.M, Langefeld C.D. Genetics of autoim-mune diseases: insights from population genetics. Journal of Human Genetics 2015 Nov; 60(11): 657–64.

6. Taneja V., Mangalam A., David C.S. Chapter 27. Genetic predis-position to autoimmune diseases conferred by the major histocompatibility complex: utility of animal models. In: Rose N., Mackay I., editors. The Autoimmune Diseases, 5th edition. San Diego, CA: Academic Press/Elsevier 2014. p. 365-80. Available from: https://doi.org/10.1016/C2009-0-64586-4

7. Wanstrat A., Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nature Immunology 2001 Sept 01; 2(9): 802–9.

8. Oldstone M.B. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Current Topics in Microbiology and Immunology 2005; 296: 1–17.

9. Fujinami R.S., Oldstone M.B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985; 230: 1043–1045.

10. Trost B., Lucchese G., Stufano A., Bickis M., Kusalik A., Kanduc D. No human protein is exempt from bacterial motifs, not even one. Self/Nonself 2010; 1(4): 328–34.

11. Hebbes T.R., Turner C. H., Thorne A. W., Crane-Robinson C. A "minimal epitope" anti-protein antibody that recognizes a single modified amino acid. Mol Immunol 1989 Sep; 26(9):865-73.

12. Forsström B., Bisławska Axnäs B., Stengele K.-P., Bühler J., Albert T. J., Richmond T. A., Hu F. J., Nilsson P., Hudson E. P., Rockberg J., Uhlen M.. Proteome-wide epitope mapping of antibodies using ultra-dense peptide arrays. Mol Cell Proteomics 2014; 13: 1585–1597.

13. Peng H. P., Lee K. H., Jian J. W., Yang A. S. Origins of specificity and affinity in antibody-protein interactions. Proc Natl Acad Sci USA 2014; 111: E2656–2665.

14. Pahari S., Chatterjee D., Negi S., Kaur J., Singh B., Agrewala J.N. Morbid sequences suggest molecular mimicry between microbial peptides and self-antigens: a possibility of inciting autoimmunity. Front Microbiol 2017 Oct 9; 8: 1938.

15. Sanchez-Trincado J.L., Gomez-Perosanz M., Reche P.A. Funda-mentals and methods for T- and B-cell epitope prediction. Journal of Immunology Research 2017; 2017: Article ID 2680160, 14 pages.

16. Lafuente E.M., Reche P.A. Prediction of MHC-peptide binding: a systematic and comprehensive overview. Current Pharmaceutical De-sign 2009; 15(28): 3209–20.

17. Jensen P.E. Recent advances in antigen processing and presentation. Nature Immunology 2007; 8(10): 1041–48.

18. Wilson D.B., Wilson D.H., Schroder K., Pinilla C., Blondelle S., Houghten R.A., Garcia K.C. Specificity and degeneracy of T cells. Mol Immunol. 2004 Feb; 40(14-15):1047-55.

19. Wucherpfennig K.W. T cell receptor crossreactivity as a general property of T cell recognition. Mol Immunol 2004 Feb; 40(14-15): 1009-17.

20. Petrova G., Ferrante A., Gorski J. Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol 2012; 32(4): 349-72.

21. Bentzen A.K., Hadrup S.R. T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation. Immuno-Oncology Technology, 2019 Sept; 2: 1-10.

22. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19: 395–404.

23. Münz C., Lünemman J.D., Getts M.T., Miller S.D. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009 Apr; 9(4): 246–58.

24. Nino-Vasquez J., Allicotti G., Borras E., Wilson D. B., Valmori D., Simon R., Martin R., Pinilla C.. A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol Immunol 2004 Feb; 40(14-15): 1063-74.

25. Dhanda S. K., Gupta S., Vir P., Raghava G.P. Prediction of IL4 inducing peptides. Clin Dev Immunol 2013; 263952.

26. Dhanda S.K., Vir P., Raghava G.P. Designing of interferon-gamma inducing MHC class-II binders. Biol Direct 2013; 8:30.

27. Shahrizaila N., Yuki N. Guillain-Barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. Journal of Biomedicine and Biotechnology 2011 Dec 15; 2011: Article ID 829129, 5 pages.

28. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A.C. Campylobacter jejuni infection and Guillain-Barré syndrome. The New England Journal of Medicine 1995; 333(21): 1374–79.

29. 29Schwimmbeck P.L, Dyrberg T., Drachman D., Oldstone M.B.A. Molecular mimicry and myasthenia gravis: an autoantigenic site of the acetylcholine receptor α -subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989 Oct; 84(4): 1174–80.

30. 30Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999 Feb 26; 283(5406): 1335–9.

31. 31Gangaplara A, Massilamany C, Brown DM, Delhon G, Pattnaik AK, Chapman N, Rose N, Steffen D, Reddy J. Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-alpha-reactive CD4 T cells in A/J mice. Clinical Immunology. 2012 Sept; 144(3): 237–49.

32. Regner M., Lambert P.H. Autoimmunity through infection or im-munization? Nat Immunol 2001; 2(3): 185–8.

33. Filippi C.M., von Herrathi M.G. Viral trigger for type I diabetes. Pros and Cons Diabetes 2008 Nov; 57(11): 2863–2871.

34. Honeyman M.C., Stone N.L., Falk B.A., Nepom G., Harrison L.C. Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens. J Immunol. 2010 Feb 15; 184(4): 2204–10.

35. Roep B.O., Hiemstra H.S., Schloot N.C., de Vries R.R.P, Chaudhuri A., Behan P.O., Drijfhout J.W. Molecular mimicry in type I diabetes: immune cross-reactivity between islet autoantigen and human cytomegalovirus but not coxsackie virus. Ann N Y Acad Sci 2002 Apr; 958: 163-5.

36. Fairweather D., Frisancho-Kiss S., Rose N.R. Viruses as adjuvants for autoimmunity: evidence from coxsackievirus-induced myocarditis. Rev Med Virol 2005 Jan-Feb; 15(1): 17-27.

37. Getts M.T., Miller S.D. 99th Dahlem conference on infection, in-flammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol 2010 Apr; 160(1): 15–21.

38. Root-Bernstein R. Rethinking molecular mimicry in rheumatic heart disease and autoimmune myocarditis: laminin, collagen IV, CAR, and B1AR as initial targets of disease. Front Pediatr 2014 Aug 19; 2: 85.

39. Bachmaier K., Neu N., de la Maza L.M., Pal S., Hessel A., Penninger J.M. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999 Feb 26; 283(5406): 1335-9.

40. Ang C.W., Jacobs B.C., Laman J.D. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol 2004 Feb; 25(2): 61-6.

41. Rose N.R. The adjuvant effect in infection and autoimmunity. Clin Rev Allergy Immunol 2008 Jun; 34(3): 279-82.

42. Pradhan V.D., Das S., Surve P., Ghosh K. Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus. Indian J Hum Genet 2012 May; 18(2): 155–160.

43. Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 2006 Feb; 39(1): 41-54.

44. Montes C.L., Acosta – Rodríguez E.V., Merino M.C., Bermejo D.A., Gruppi A. Polyclonal B cell activation in infections: infectious agents’ devilry or defense mechanism of the host? J Leukoc Biol 2007 Nov; 82(5): 1027–32.

45. Bogner U., Wall J. R., Schleusener, H. Cellular and antibody mediated cytotoxicity in autoimmune thyroid disease. Acta Endocrinologica 1987; 116(1 Suppl), S133–S138.

46. Russell J.H., Ley T.J. Lymphocyte-mediated cytotoxicity. Annual Review of Immunology 2002 Febr; 20(6): 323-70.

47. Raúl V., Romána G., Murrayb J.C., Weiner L.M. Chapter 1. Anti-body-dependent cellular cytotoxicity (ADCC). In: Ackerman M.E., Nimmerjahn F., editors. Antibody Fc. Linking adaptive and innate immunity. San Diego, CA, Elsevier/Academic Press 2014. p. 1-27. Available from: https://doi.org/10.1016/C2011-0-07091-6

48. Varela J.C., Tomlinson S. Complement: an overview for the clini-cian. Hematol Oncol Clin North Am 2015 Jun; 29(3): 409-27.

49. Liblau R.S., Wong F.S., Mars L.T., Santamaria P. Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for thera-peutic intervention. Immunity 2002 July; 17(1): 1-6.

50. Ma W-T., Gao F., Gu K., Chen D-K. The role of monocytes and macrophages in autoimmune diseases: a comprehensive review. Front Immunol 2019 May 24; 10: 1140.

51. Schleinitz N., Vély F., Harlé J.-R., Vivier E. Natural killer cells in human autoimmune diseases. Immunology. 2010 Dec; 131(4): 451–458.

52. Lehmann P.V., Targoni O.S., Forsthuber T.G. Shifting T-cell activation thresholds in autoimmunity and determinant spreading. Immunol Rev 1998 Aug; 164(1): 53–61.

53. Cunningham M.W. Rheumatic fever, autoimmunity and molecular mimicry: the streptococcal connection. Int Rev Immunol. 2014 Jul-Aug; 33(4): 314–29.

54. Cohen I.R., Young D.B. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991 Apr; 12(4): 105–10.

55. Fujinami R.S., von Herrath M.G., Christen U., Whitton J.L. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clinical microbiology reviews 2006 Jan; 19(1): 80–94.

56. Pane J.A., Coulson B.S. Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes. Diabetologia 2015 Jun; 58(6): 1149 –59.

57. Lee H-G., Lee J-U., Kim D-H., Lim S., Kang I., Choi J-M. Pathogenic function of bystander-activated memory-like CD4+ T cells in autoimmune encephalomyelitis. Nature Communications 2019 Febr 12; 10: Article number 709.

58. Nogai A., Siffrin V., Bonhagen K., Pfueller C.F., Hohnstein T., Volkmer-Engert R., Brück W., Stadelmann C., Kamradt T. Lipopolysac-charide injection induces relapses of experimental autoimmune encephalomyelitis in nontransgenic mice via bystander activation of autoreactive CD4 cells. The Journal of Immunology 2005 Jul 15; 175(2): 959–66.

59. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009 Apr; 21(4): 317–37.

60. El-Zayat S.R., Sibaii H., Mannaa F.A. Toll-like receptors activation, signaling, and targeting: an overview. Bull Natl Res Cent 2019 Dec 12; 43(1): 187.

61. Chiffoleau E. C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front Immunol 2018 Feb 15; 9: 227.

62. Kim Y.K., Shin J.S., Nahm M.H. NOD-like receptors in infection, immunity, and diseases. Yonsei Med J 2016 Jan; 57(1): 5-14.

63. Loo Y-M., Gale M. Immune signaling by RIG-I-like receptors. Im-munity 2011 May 27; 34(5): 680–692.

64. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S. et al. Toll-like receptor engagement covers T-cell autoreactivity into overt autoimmune disease. Nat Med 2005 Febr; 11(2): 138-45.

65. Haas A., Zimmermann K., Oxenius A. Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. Journal of virology 2011 Dec; 85(23): 12102–113.

66. Shoenfeld Y., Agmon-Levin N. ‘ASIA’–Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011; 36: 4–8.

67. Hawkes D., Benhamu J., Sidwell T., Miles R., Dunlop R.A. Revisiting adverse reactions to vaccines: a critical appraisal of autoimmune syndrome induced by adjuvants (ASIA). J Autoimmun 2015 May; 59: 77–84.

68. Soriano A., Nesher G., Shoenfeld Y. Predicting post-vaccination autoimmunity: Who might be at risk? Pharmacol Res 2015 Feb; 92: 18–22.

69. van der Laan J.W., Gould S., Tanir J.Y. Safety of vaccine adju-vants: focus on autoimmunity. Vaccine 2015 Mar 24; 33(11): 1507–14.

70. Domiati-Saad., R., Attrep J.F., Brezinschek H.P., Cherrie A.H., Karp D.R., Lipsky P.E. Staphylococcal enterotoxin D functions as a human B-cell superantigen by rescuing VH4-expressing B cells from apoptosis. J Immunol. 1996 May 15; 156(10): 3608-20.

71. Domiati-Saad R., Lipsky P.E. Staphylococcal enterotoxin A induces survival of VH3-expressing human B cells by binding to the VH region with low affinity. J Immunol 1998 Aug 1; 161(3): 1257-1266.

72. Viau M., Longo N.S., Lipsky P.E., Björck L., Zouali M. Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L. Infect Immun 2004 Jun; 72(6): 3515–23.

73. Karray S., Juompan L., Maroun R. C., Isenberg D., Silverman G. J., Zouali M. Structural basis of the gp120 superantigen-binding site on human immunoglobulins. 1998 Dec 15; 161(12): 6681-8.

74. Wikström M, Sjöbring U, Drakenberg T, Forsén S, Björck L. Map-ping of the immunoglobulin light chain-binding site of protein L. J Mol Biol 1995 Jul 7; 250(2): 128-33.

75. Nilson B.H., Solomon A., Björck L., Akerström B. Protein L from Peptostreptococcus Magnus binds to the kappa light chain variable domain. 1992 Feb 5; 267(4): 2234-9.

76. Schiffenbauer J. Superantigens and their role in autoimmune dis-orders. Archivum Immunologiae et Therapiae Experimentalis 1999; 47(1): 17–24.

77. Rott, O., Charreire, J., Cash, E. Influenza A virus hemagglutinin is a B cell-superstimulatory lectin. Med. Microbiol. Immunol 1996 Feb; 184(4): 185–93.

78. Ram M. The putative protective role of hepatitis B virus (HBV) in-fection from autoimmune disorders. Autoimmunity 2008 Sep; 7(8): 621–25.

79. Watanabe K., Kumada H., Yoshimura F., Umemoto T. The induc-tion of polyclonal B-cell activation and interleukin-1 production by the 75-kDa cell surface protein from Porphyromonas gingivalis in mice. Arch Oral Biol 1996 Aug-Sep; 41(8-9): 725–31.

80. Murphy K., Travers P., Walport M. Сhapter 5. Antigen presentation to T-lymphocytes. In: Murphy K., Travers P., Walport M., editors. Janeway's Immunobiology. 7th edition. New York. USA: Garland Science 2008. p. 206—7. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10766/

81. Cordeiro-Da-Silva A., Borges M.C., Guilvard E., Ouaissi A. Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation. Infect Immun 2001 Nov; 69(11): 6588 –96.

82. Chung N.P.Y., Matthews K., Klasse P.J., Sanders R.W., Moore J.P. HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells J Immunol 2012 Dec 1; 189(11): 5257–65.

83. Dörner T., Giesecke C., Lipsky P.E. Mechanisms of B cell autoimmunity in SLE. Arthritis Research and Therapy 2011 Oct 27; 13(5): 243, 12 p.

84. Proft T., Fraser J.D. Bacterial superantigens. Clin Exp Immunol 2003 Sep; 133(3): 299–306.

85. Schiffenbauer J. Superantigens and their role in autoimmune dis-orders. Arch Immunol Ther Ex 1999; 47(1): 17–24.

86. Strachan, D. Family size, infection and atopy: The first decade of the "hygiene hypothesis". Thorax 2000 Aug; 55(Suppl 1): 2–5.

87. Rook G.A.W. Microbes, immunoregulation, and the gut. Gut 2005 Mar; 54(3): 317–20.

88. Kiseleva E.P., Novik G.I. Probiotics as immunomodulators: sub-stances, mechanisms and therapeutic benefits. In: Mendez-Vilas A., editor. Microbial pathogens and strategies for combating them: science, technology and education. Badajoz, Spain: Formatex Research Center 2013. 3: 1864–76. https://api.semanticscholar.org/CorpusID:42172455